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A New Method for Targeted and 
Sustained Induction of Type 2 
Diabetes in Rodents
Dino Premilovac1, Robert J. Gasperini1, Sarah Sawyer1, Adrian West1, Michelle A. Keske2,3, 
Bruce V. Taylor  2 & Lisa Foa1
Type 2 diabetes is a chronic metabolic disorder that is becoming a leading cause of morbidity and 
mortality. The prolonged time-course of human type 2 diabetes makes modelling of the disease 
difficult and additional animal models and methodologies are needed. The goal of this study was to 
develop and characterise a new method that allows controlled, targeted and sustained induction of 
discrete stages of type 2 diabetes in rodents. Using adult, male rats, we employed a three-week high 
fat-diet regimen and confirmed development of obesity-associated glucose intolerance, a key feature 
of human type 2 diabetes. Next, we utilised osmotic mini-pumps to infuse streptozotocin (STZ; 
doses ranging 80–200 mg/kg) over the course of 14-days to decrease insulin-producing capacity thus 
promoting hyperglycemia. Using this new approach, we demonstrate a dose-dependent effect of STZ 
on circulating glucose and insulin levels as well as glucose tolerance, while retaining a state of obesity. 
Importantly, we found that insulin secretion in response to a glucose load was present, but reduced in a 
dose-dependent manner by increasing STZ. In conclusion, we demonstrate a novel method that enables 
induction of discrete stages of type 2 diabetes in rodents that closely mirrors the different stages of type 
2 diabetes in humans.
Among the different forms of diabetes, type 2 diabetes accounts for approximately 90% of cases and current esti-
mates indicate that by 2040, approximately 642 million world-wide people will be living with type 2 diabetes1,2. 
This is likely to be a conservative estimate given that for every case of diagnosed type 2 diabetes, we know there is 
likely an additional, undiagnosed case1,2. This is most concerning in developing countries where as many as 50% 
of diabetics are undiagnosed and living with uncontrolled hyperglycemia1,2, the primary risk factor for develop-
ment of cardiovascular, metabolic and neuronal disorders associated with the disease3–6. Therefore, development 
of animal models that accurately replicate the pathogenesis of human type 2 diabetes is of paramount importance 
and will enable identification of preventative and therapeutic strategies targeting both type 2 diabetes and asso-
ciated pathologies.
Type 2 diabetes is a complex, chronic disorder and most people with type 2 diabetes progress through an early 
stage of obesity-associated insulin resistance prior to development of frank hyperglycemia5,6. With continuing 
insulin resistance, a compensatory increase in insulin production maintains normal circulating glucose concen-
trations5–7. This physiological shift impacts pancreatic beta cells early in disease progression and with time, leads 
to exhaustion of beta cell insulin production, clinically manifesting as frank type 2 diabetes6. The time-course of 
pre-clinical and then clinical type 2 diabetes progression can be incredibly long and thus makes modelling dis-
crete stages of type 2 diabetes incredibly difficult.
With the exception of genetic models, which are costly and do not accurately model human type 2 diabe-
tes, the most commonly used animal model of type 2 diabetes is the high fat diet (HFD) fed rodent injected 
with streptozotocin (STZ)8–12. This model accelerates the time-course of type 2 diabetes by initiating a state of 
obesity-associated insulin resistance using a period of HFD feeding7,13, followed by an injection of STZ to deplete 
pancreatic beta cells8,14. A few days after STZ administration, these animals develop severe hyperglycemia in the 
near absence of insulin production, exhibit marked weight loss and have short life expectancy15. These physi-
ological changes currently confine the HFD + STZ model to investigation of end-stage type 2 diabetes, which 
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more closely resembles type 1 diabetes16,17. Some studies have utilised multiple low-dose STZ injections and 
argue that this approach enables better control of the ensuing hyperglycemia based on the notion that smaller, 
repeated insults impart greater control over the extent of beta cell death18,19. However, while leading to short-term 
hyperglycemia, long-term studies (≥four weeks) are confounded by the ability of the remaining beta cells to 
compensate/regenerate resulting in a reversion toward normoglycemia20,21. This is particularly evident in younger 
rodents and suggests that the efficacy of injection methods may also be markedly influenced by the age at which 
STZ is injected20,21. Given these limitations, the aim of the current study was to develop a new animal model that 
allows targeted and sustained induction of discrete stages of type 2 diabetes where animals remain obese, exhibit 
mild-moderate hyperglycemia and retain the ability to produce insulin, or those that exhibit frank type 2 diabetes.
Results
STZ is stable over a 14-day period. Due to the slow release of STZ from the mini-pump, we first inves-
tigated the stability of STZ in citrate buffer across 14-days (delivery period of the mini-pump) at 37 °C. Over the 
course of two-weeks, STZ degradation was approximately 20% (Fig. 1A). The ratio of alpha/beta STZ anomers 
reached equilibrium (43/57%, respectively) within the first two hours of dissolution and remained constant across 
the two-week period (Fig. 1B).
Rats given a HFD and osmotic mini-pump-infused STZ exhibited increased body weight and 
adiposity. While water intake was not altered by HFD, food intake was greater in all HFD-fed groups rela-
tive to control diet (CD) across the first three weeks (Supplementary Table 1). In all groups, HFD feeding led to 
increased body weight compared CD-fed rats across the first three weeks and only the two highest doses of STZ 
(150 mg/kg and 200 mg/kg) led to weight loss at the end of the five-week period (Fig. 2B). Epididymal fat mass (a 
surrogate marker of adiposity) was approximately 2-fold higher in all HFD-fed animals compared to CD (p < 0.05 
for all) with the exception of the 150 mg/kg and 200 mg/kg STZ groups (Fig. 2C), where there was no difference. 
Similarly, all HFD fed rats exhibited 2–3 fold higher circulating non-esterified fatty acid (NEFA) concentrations 
relative to CD (Fig. 2D; p < 0.001 for all).
Figure 1. Streptozotocin is stable over 14 days. (A) The total concentration of STZ was determined every two 
days from dissolution in citrate buffer using HPLC and plotted as percent change from day 0 (representing 
100%). (B) The relative amount of each STZ anomer was also monitored using HPLC over the first 100 min 
post-dissolution and then every two days thereafter. Data are means ± SEM for n = 4 independent solutions of 
STZ.
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Figure 2. Osmotic mini-pump delivered STZ does not cause weight loss and animals retain an obesogenic 
phenotype. (A) Thirty-five day protocol for induction of type 2 diabetes using osmotic mini-pump infused STZ. 
Blood drops indicate assessment of body weight, food and water intake and non-fasting glucose concentrations. 
Glucose tolerance (1 g/kg; GTT) was assessed in each animal on days 0, 20 and 35. (B) Body weight plotted 
for day 0 (white bars), day 20 (closed bars) and day 35 (hatched bars). (C) Epididymal fat pads were excised 
and weighed at the end of the experiment (day 35) and presented as percent of total body weight to adjust for 
differences in total body weight across the groups. (D) Circulating non-esterified fatty acids were assessed on 
day 35 for all but the 150 and 200 mg/kg STZ groups where insufficient blood could be collected due to poor tail 
blood flow. Data are mean ± SEM for n = 6 in all groups except 150 mg/kg and 200 mg/kg STZ groups where 
n = 3. *p < 0.05 versus day 0 within the group; and †p < 0.05 versus days 0 and 20 within the group using two-
way repeated measures ANOVA. #p < 0.05 versus CD using one-way ANOVA on ranks.
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Osmotic mini-pump-infused STZ dose-dependently increased fasting glucose and decreased 
fasting insulin concentrations. Non-fasting glucose concentrations were assessed in all animals twice 
weekly up to day 20 and then daily from days 21–34 (Supplementary Figure 1). Six days post-mini pump implant, 
non-fasting glucose concentrations were increased, but not statistically different from vehicle at STZ doses 
ranging from 80–110 mg/kg. Animals that received 120 mg/kg STZ had increased non-fasting glucose by day 
five and this remained higher than vehicle across the reminder of the intervention (p < 0.01). The two highest 
doses of STZ tested caused a rapid and overt increase in non-fasting glucose concentrations 2–3 days following 
mini-pump implant. In both cases, glucose concentrations exceeded 20.0 mmol/l within 6–7 days’ post-implant. 
The experimental protocols in these two groups were concluded early (days 32 and 28, respectively) due to rapid 
weight loss (Fig. 2B) and animal health and wellbeing.
All animals were fasted overnight prior to glucose tolerance tests on days 0, 20 and 35. Fasting blood glucose 
concentrations were not different between groups at baseline or day 20 (Fig. 3A). On day 35, fasting glucose was 
increased in animals treated with 80 mg/kg STZ (6.7 ± 0.1 mmol/l), 90 mg/kg STZ (6.5 ± 0.3 mmol/l) and 100 mg/
kg STZ (6.4 ± 0.3 mmol/l) compared with their respective values on day 0 and day 20 (p < 0.05 for all), but did not 
reach significance versus vehicle (5.7 ± 0.3 mmol/l). Relative to vehicle, fasting glucose was increased in animals 
that received 110 mg/kg STZ (7.2 ± 0.2 mmol/l) and 120 mg/kg STZ (9.0 ± 1.3 mmol/l). Increasing STZ further to 
150 mg/kg and 200 mg/kg resulted in extreme increases in fasting glucose (p < 0.001 for both vs vehicle).
Compared with CD-fed animals (41 ± 4 pmol/l), fasting insulin concentrations (Fig. 3B) were significantly 
higher in HFD (95 ± 20 pmol/l), vehicle (91 ± 14 pmol/l), 80 mg/kg (75 ± 7 pmol/l) and 90 mg/kg (70 ± 8 pmol/l) 
STZ groups (p < 0.05 for all). In animals that received 100 mg/kg (57 ± 11 pmol/l), 110 mg/kg (50 ± 8 pmol/l) and 
120 mg/kg (43 ± 5 pmol/l) doses of STZ, fasting insulin concentrations were lower relative to vehicle (p < 0.05 
for all) but remained modestly higher than CD-fed rats. Unfortunately, due to poor blood circulation in the tails 
of animals that received 150 mg/kg and 200 mg/kg STZ, we could not collect enough blood to determine insulin 
Figure 3. Osmotic mini-pump-infused STZ dose-dependently increased fasting glucose concentrations and 
reduced fasting insulin concentrations. (A) Fasting blood glucose concentrations were determined following an 
overnight fast on days 0 (open bars), 20 (closed bars) and 35 (hatched bars). The exception was 150 mg/kg and 
200 mg/kg STZ groups where experiments ended on days 32 and 28 respectively for animal welfare. Data are 
mean ± SEM for n = 6 in all groups, except 150 mg/kg and 200 mg/kg STZ groups where n = 3. (B) On day 35, 
blood was collected prior to GTT and fasting plasma insulin determined. Data are mean ± SEM for n = 6 in all 
groups except 150 mg/kg and 200 mg/kg STZ groups where no samples could be collected due to poor tail blood 
flow. *p < 0.05 versus day 0 within the group; †p < 0.05 versus days 0 and 20 within the group; §p < 0.05 versus 
vehicle and the preceding dose of STZ at day 35 using two-way repeated measures ANOVA. #p < 0.05 versus 
CD; and ‡p < 0.05 versus vehicle at day 35 using one-way ANOVA on ranks.
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concentrations in these animals, but based on the characteristics of these animals it is highly likely that both 
groups had very low circulating insulin.
Osmotic mini-pump-infused STZ dose-dependently decreased glucose tolerance. Glucose tol-
erance was assessed on day 0, day 20 and day 35 using a 1 g/kg i.p. injection of glucose (Fig. 4). The total exposure 
Figure 4. Osmotic mini-pump-infused STZ dose-dependently decreased glucose tolerance. Following an 
overnight fast, blood was sampled from the tip of the tail and circulating blood glucose concentrations were 
determined at 0, 10, 20, 30, 45, 60, 75, 90, 105 and 120 min after glucose injection (1 g/kg). Glucose tolerance 
tests were performed on day 0 (open circle), day 20 (closed circle) and day 35 (closed triangle) except 150 mg/
kg and 200 mg/kg STZ groups where experiments ended on days 32 and 28 respectively. (A) CD; (B) HFD; 
(C) vehicle; (D) 80 mg/kg; (E) 90 mg/kg; (F) 100 mg/kg; (G) 110 mg/kg; and (H) 120 mg/kg; (I) 150 mg/kg; 
(J) 200 mg/kg STZ. Data are mean ± SEM for n = 6 in all groups except 150 mg/kg and 200 mg/kg STZ groups 
where n = 3. *p < 0.05 versus day 0 within the group; and ***p < 0.05 versus both days 0 and 20 at all time-
points under the line using two-way repeated measures ANOVA.
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to glucose during the glucose tolerance test was quantified by calculating the area under the curve (AUC) for each 
test (Fig. 5A). On day 20 all HFD-fed rats exhibited significantly higher glucose concentrations across the first 
30 min (Fig. 4B; p < 0.05), culminating in a significant increase in total glucose AUC relative to day 0 across all 
groups (Fig. 5A; p < 0.01). On day 35, glucose tolerance was not different between HFD and vehicle treated rats 
(Figs 4B,C and 5A). Animals that received 80–100 mg/kg STZ exhibited significantly increased glucose concen-
trations from 30–90 min (p < 0.05) but returned toward baseline over the final 30 min of the glucose tolerance test 
(Fig. 4D–F). All three STZ groups exhibited a marked increase in AUC during the glucose tolerance test relative 
to vehicle treated rats (Fig. 5A). Treatment with 110 mg/kg STZ caused a further decline in glucose tolerance and 
glucose concentrations remained significantly elevated relative to baseline across the time-course of the glucose 
tolerance test (Fig. 4G; p < 0.01). Increasing STZ further to 120 mg/kg, 150 mg/kg and 200 mg/kg resulted in 
step-wise increases in glucose concentrations across the 120 min test where there was minimal return baseline 
(Fig. 4H–J). These findings were mirrored by step-wise increases in glucose AUC during the glucose tolerance test 
for each dose of STZ (Fig. 5A; p < 0.001 vs vehicle and preceding STZ dose for all). Plotting the STZ dose versus 
the resulting AUC (Fig. 5B) revealed a tight sigmoidal, dose-dependent relationship where STZ appears to have 
small effects on glucose tolerance at 80 mg/kg and near maximal effects at 150 mg/kg.
Osmotic mini-pump-infused STZ reduced insulin release during a glucose tolerance 
test. Plasma was collected at 0, 10, 20 and 60 min during the day-35 glucose tolerance test (Fig. 6) in all 
groups with the exception of the 150 and 200 mg/kg STZ groups. In CD-fed animals, a significant rise in plasma 
insulin concentrations was detected 10 min following glucose injection (41 ± 4 vs. 155 ± 32 pmol/l; p < 0.001) but 
quickly returned toward baseline at 20 (73 ± 8 pmol/l; p = 0.482) and 60 min (48 ± 5 pmol/l; p = 0.786). Both the 
HFD-only and HFD+ vehicle treated groups had higher plasma insulin concentrations at 10 min (287 ± 42 and 
249 ± 32 pmol/l), 20 min (257 ± 76 and 286 ± 49 pmol/l) and 60 min (110 ± 25 and 156 ± 12 pmol/l) compared 
with CD (p < 0.05 for all time-points). Animals that received 80 mg/kg STZ had modest increases in insulin 
concentrations at 10 min (125 ± 14 pmol/l; p = 0.291), 20 min (116 ± 10 pmol/l; p = 0.151) and 60 min (121 ± 25 
pmol/l; p = 0.244) relative to their baseline. Similarly, at 90 mg/kg STZ, circulating insulin increased modestly 
following glucose injection at 10 min (102 ± 25 pmol/l; p = 0.265), 20 min (133 ± 22 pmol/l; p = 0.127) and 
60 min (111 ± 20 pmol/l; p = 0.319) relative to bassline. At 100 mg/kg STZ, insulin concentrations were higher 
at 10 min (102 ± 23 pmol/l; p = 0.387), but returned toward baseline at 20 min (75 ± 19 pmol/l; p = 0.522) and 
Figure 5. Osmotic mini-pump-infused STZ dose-dependently increased glucose exposure during a glucose 
tolerance test. (A) The area under the glucose curve (AUC) was calculated for glucose tolerance test at each 
of the three time-points (day 0 [open bars], day 20 [closed bars] and 35 [hatched bars]) using the trapezoidal 
method. (B) A dose-response curve was generated by plotting AUC measures versus STZ dose. Data are 
mean ± SEM for n = 6 in all groups except 150 mg/kg and 200 mg/kg STZ groups where n = 3. *p < 0.05 versus 
day 0 within the group; †p < 0.05 versus days 0 and 20 within the group; ‡p < 0.05 versus vehicle at day 35; and 
§p < 0.05 versus vehicle and the preceding dose of STZ at day 35 using two-way repeated measures ANOVA.
www.nature.com/scientificreports/
7SCIENTIFIC REPORTS | 7: 14158  | DOI:10.1038/s41598-017-14114-4
60 min (79 ± 16 pmol/l; p = 0.709). Relative to vehicle treated animals, the rats that received 80, 90 and 100 mg/
kg STZ exhibited reduced insulin concentrations at 10 and 20 min following glucose administration (Fig. 6; 
p < 0.001 for all). Animals that received 110 mg/kg and 120 mg/kg STZ did not exhibit increased insulin levels at 
any time-points following glucose administration and had lower insulin concentrations relative to vehicle treated 
animals at all time-points (Fig. 6; p < 0.05 for all).
Pancreatic tissue was collected from each animal and representative sections are shown for each group 
(Supplementary Figure 2). Islets from CD, HFD and vehicle (panels A–C) treated animals had similar structure 
and stained heavily for insulin/pro-insulin. At STZ doses of 80–120 mg/kg, there appeared to be a step-wise 
decline in islet staining for insulin/pro-insulin, while islet structure shifted from oval toward irregular in shape 
(panels D–H). Very few islets were present in sections from 150 mg/kg and 200 mg/kg STZ groups (panels I and 
J) and when located, exhibited almost no staining for insulin/pro-insulin.
Discussion
In the present study, we demonstrate a novel method that allows for targeted and sustained induction type 2 
diabetes in rats by combining a HFD with osmotic mini-pump-infused STZ. In our model, HFD feeding led to 
obesity, increased circulating NEFA and insulin concentrations and glucose intolerance, typical of insulin resist-
ance/pre-diabetes in both rodents7,22 and humans23. The addition of STZ after three weeks of HFD feeding caused 
a dose-dependent increase in circulating glucose and further decline in glucose tolerance while preserving an 
obese, dyslipidemic phenotype. Critically, the dose-dependent decline in glucose tolerance was accompanied by 
a reciprocal, dose-dependent decrease in insulin secretion in response to the glucose load. Thus, for the first time 
our novel approach enables targeted induction of type 2 diabetes across the spectrum of disease. This approach 
is a significant advance for modelling distinct stages of type 2 diabetes (i.e. during the phase of declining beta cell 
function) that ultimately provides a powerful platform for modelling type 2 diabetes and associated pathologies.
Once in the circulation, STZ is transported into pancreatic beta cells by the glucose transporter 2 (GLUT2) 
protein24,25. Within the beta cell, STZ interrupts a number of important cellular processes and if the insult is 
sufficient, culminates in DNA damage and cell death24,25. The end result of STZ administration is the reduction 
of functional beta cell mass that manifests as insulin deficiency and subsequent inability to handle glucose25. 
Coupling this insulin insufficiency with the challenge of a HFD, where increased insulin is required to account 
for cellular insulin resistance26,27, induces a state of glucose intolerance8, typical of human type 2 diabetes. In 
the present study, we demonstrate that the combination of HFD + STZ infused by osmotic mini-pump enables 
excellent phenotypic control with targeted induction of hyperglycemia and glucose intolerance, while maintain-
ing a state of obesity. Furthermore, we confirmed that the dose-dependent effect of STZ we observed is due to a 
reciprocal reduction in insulin secretory capacity and morphological changes to the pancreas. To our knowledge, 
no other method currently allows such precise control over the resulting level of hyperglycaemia and glucose 
intolerance. Therefore, we believe this is the first animal model capable of reproducing different stages of type 2 
diabetes defined by dose-dependent effects of STZ on glucose intolerance, reduced beta cell function and ensuing 
hyperglycemia while retaining an obese dyslipidemic profile.
All current methods for delivering STZ employ injections (e.g. IP or IV). Whilst these are exclusively utilised 
in the literature (due to the prevailing notion that STZ degrades quickly in solution), injection methods also 
impose significant limitations to the resulting phenotype. IP injections yield highly variable results due to the 
exact injection site and thus influences the absorbance rate of STZ into the systemic circulation. This may account 
for some of the inconsistencies in the literature where similar doses of STZ (e.g. 35 mg/kg) are reported to have 
very different effects on glucose tolerance8,28,29. Similar issues confound studies using IV injection to administer 
STZ, where at the same dose as IP (35 mg/kg), IV injections are reported to be just as variable in their effective-
ness30,31. Generally, the IV method appears to be preferred, likely due to a more targeted and direct mode of 
delivery15. However, relative to IP, IV injections are more technically challenging without providing significant 
improvement over the resulting level of hyperglycemia. A recent study in guinea pigs demonstrated that subcu-
taneous injection of STZ (200 mg/kg) could improve overall efficacy but only when animals are also treated with 
Figure 6. Osmotic mini-pump-infused STZ reduced insulin secretion during a glucose tolerance test. Blood 
was collected at 0 (open bars), 10 (closed bars), 20 (diagonal hatch) and 60 min (horizontal hatch) into the 
glucose tolerance test and insulin concentrations quantified. Data are mean ± SEM for n = 6 in all groups 
except 150 mg/kg and 200 mg/kg STZ groups where no samples could be collected due to poor tail blood flow. 
*p < 0.05 versus 0 min within the group; #p < 0.05 versus CD at the same time-point; and ‡p < 0.05 versus 
vehicle at the same time-point using two-way repeated measures ANOVA.
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the α-adrenergic receptor antagonist yohimbine12. In the present study, we show consistent, reproducible and 
dose-dependent effects by utilising subcutaneously implanted osmotic mini-pumps to infuse STZ over the course 
of 14 days.
Injection methods cause spikes in circulating STZ concentrations and as such, STZ has a very short time-frame 
to affect pancreatic beta cells. Whether this short, single-pass insult to the beta cells is sufficient to induce cell 
death is highly dependent on the dose of STZ utilised. Indeed, animals injected with lower STZ doses (15–30 mg/
kg IP or IV) have been reported to revert back to normoglycemia, and thus require repeat low-dose injections to 
maintain the hyperglycaemic phenotype18. Conversely, animals injected with higher STZ doses (≥50 mg/kg IP or 
IV) exhibit overt hyperglycemia, complete absence of insulin, weight loss and as such are prone to a high mortal-
ity rate15,18,32. In support of one previous study33 and in contrast the prevailing belief that STZ degrades quickly, 
we report that STZ undergoes an isomer switch and remains relatively stable for at least 14 days. This opens the 
door to novel avenues of STZ administration, such as the osmotic mini-pump, where STZ can be released slowly 
and consistently into the circulation over 14 days. Therefore, rather than a large spike in STZ, cells are exposed to 
low circulating concentrations of STZ resulting in a sustained 14-day insult. Importantly, even though circulating 
STZ concentration is relatively low compared to injection methods, the sensitivity of beta cells to STZ-induced 
damage is evident from the rapid and sustained effects on glucose handling, circulating insulin and pancreatic 
histology. Thus, we conclude that the overall improvement in effectiveness observed in our study is likely due 
to sustained, chronic exposure of STZ to beta cells. Our data suggest that a sustained low-grade insult to beta 
cells produces more consistent and precise effects than that of a large dose with single-pass uptake. Therefore, 
administering STZ using osmotic mini-pumps imparts significantly greater control over the resulting level of 
hyperglycemia while retaining an obesogenic phenotype.
From an animal welfare perspective and in accordance with the NC3Rs and the ARRIVE guidelines for ani-
mal research34, our effective STZ dose range of 80–120 mg/kg led to consistent metabolic effects in all animals 
(zero non-responders) and resulted in zero inadvertent animal deaths. While these statistics are generally poorly 
reported in the literature as a whole, our method is a marked improvement on previous publications where ani-
mals either do not respond to STZ injection (~10–15%) or die as a result of STZ injection (≥30%)15,33. Taken 
together, these data demonstrate that our new method required fewer animals to observe significant effects com-
pared with previous reports15,33. As noted above, the improvement in efficacy that we observed is likely due to the 
prevailing concentration of STZ in the circulation following injection (very high) or osmotic mini-pump infusion 
(very low) and the resulting effects on not just the highly sensitive beta cells, but also all other cells in the body.
It should be noted that while our method is a significant advance in the field, the HFD + STZ model itself 
remains somewhat artificial with regard to human type 2 diabetes pathogenesis. Indeed, individuals with type 2 
diabetes progress through a far longer stage of insulin resistance-associated hyperinsulinemia, which ultimately 
leads to beta cell dysfunction5,6. While our model involves a background of HFD-induced insulin resistance7,22, 
the administration of STZ does not replicate the exact cause of beta cell death as seen in humans. While this 
imposes some limitations on this model, the use of STZ greatly accelerates the time-frame for development of 
hyperglycemia and glucose intolerance that may not otherwise occur in rodents with relatively short life-spans. 
Importantly, the result of both human type 2 diabetes and STZ administration is the same, development of sus-
tained hyperglycemia, which ultimately drives the pathological features of type 2 diabetes such as microvascular 
disease, neuropathies and nephropathy.
In conclusion, our new approach provides a significant advance and enables induction of distinct stages of 
clinical type 2 diabetes in rodents. Ultimately, this new model provides a powerful platform for identification 
of preventative and therapeutic strategies targeting the spectrum of type 2 diabetes and associated pathologies.
Materials and Methods
Stability of STZ across 14 days. The stability of STZ over the 14 day delivery period of the osmotic mini-
pump was determined using reverse-phase high performance liquid chromatography (HPLC) as previously 
described33. Briefly, four independent STZ solutions (3.5 mg/ml) were prepared in citrate buffered saline (pH 4.4) 
and kept in the dark at 37 °C for 14 days. STZ (40 µl) was injected into a C18 column (5 µm, Gemini, Phenomenex, 
CA, USA) and analysed under isocratic conditions using a flow rate of 1.0 ml/min with a 3% methanol/97% ace-
tate buffer (pH 4.4) and detection at a wavelength of 250 nm. To investigate the α and β STZ anomer equilibration 
dynamics, each solution was sampled at 0, 20, 40, 60, 80 and 100 min after dissolution. To investigate STZ degra-
dation across 14 days, each solution was subsequently sampled every two days after dissolution.
Animal husbandry. All experimental procedures were approved by the University of Tasmania Animal 
Ethics Committee and performed in accordance with the Australian Code for the Care and Use of Animals for 
Scientific Purposes – 2013, 8th Edition. Male Sprague Dawley rats aged 14–16 weeks were obtained from the 
University of Tasmania animal facility or Monash Animal Services and allowed to acclimatise for 7 days upon 
arrival. Rats were randomised and housed in groups of three at 21 ± 2 °C with a 12 hr-12 hr light-dark cycle. All 
animals were provided with water and chow ad libitum for throughout the study. With the exception of control 
diet (CD) only fed rats, all other groups were provided with a high fat diet (HFD; 23% fat by weight; simple carbo-
hydrate replacement; Specialty Feeds, WA, Australia) ad libitum throughout the study (see Fig. 2A).
Osmotic mini-pump implantation and STZ dosage. Following three weeks of HFD, STZ (Sigma 
Aldrich, St Louis, MO, USA) was infused at a constant rate (5 µL/hr) over a 14-day period using a subcutane-
ously implanted osmotic mini-pump (Alzet Model 2ML2; Durect Corporation, Cupertino, CA, USA). Briefly, rat 
anesthesia was maintained using isoflurane throughout the surgical procedure. Following sterile preparation of 
the surgical site, a 1.5 cm incision (perpendicular to the spine) was made through the skin on the dorsum of the 
animals at the lumbar level of the spinal cord. Blunt dissection was used to separate connective tissue between the 
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skin and underlying muscle layers to allow for insertion of the osmotic mini-pump. Loaded mini-pumps were 
inserted and positioned inside the cavity between the scapulae so that delivery of solution occurred away from the 
surgical site. The incision site was sealed using dissolvable sutures and animals allowed to recover.
There are no previous reports of STZ delivery using osmotic mini-pumps. Due to the slow flow rate of the 
osmotic mini-pumps, we tested seven different STZ concentrations to establish an STZ dose-response curve. 
STZ was prepared in citrate buffered saline (0.1 mmol/l; pH 4.4) and a total volume of 2 ml was loaded into 
mini-pumps 20–30 min prior to surgical implant. The seven STZ doses we tested were; i) 200 mg/kg; ii) 150 mg/
kg; iii) 120 mg/kg; iv) 110 mg/kg; v) 100 mg/kg; vi) 90 mg/kg; and vii) 80 mg/kg (these doses represent the total 
amount of STZ delivered to the animal over 14 days). Given the flow rate of the 2ML2 pump (5 µl/hr) and assum-
ing all animals weighed 500 g on the day of implant, this would equate to STZ doses of; i) 0.25 mg/hr; ii) 0.19 mg/
hr; iii) 0.15 mg/hr; iv) 0.14 mg/hr; v) 0.13 mg/hr; vi) 0.11 mg/hr; and vii) 0.10 mg/hr over a 14-day period. These 
equated to a dose-range of 2.4–6 mg/day, far lower than the 20–100 mg/kg doses used typically in IP or IV experi-
ments8,28–31. Vehicle treated rats received mini-pumps containing citrate buffered saline (pH 4.4; 2 ml). To control 
for any diet-specific effects, two additional groups of rats were maintained on CD or HFD only for the duration of 
the 35-day protocol (Fig. 1). Thus, a total of 10 groups were used in the present study.
Assessment of metabolic alterations. Food intake, water intake, body weight and non-fasting blood 
glucose concentrations were assessed every 3–4 days for the duration of the 35-day intervention (see Fig. 2A). 
Non-fasting glucose concentrations were determined using a hand-held glucometer (Accu-Chek Performa, 
Roche Diagnostics, NSW, Australia) by making a small incision to the tip of the tail to access blood. To assess 
changes in glucose handling over the 35-day intervention each animal underwent a glucose tolerance test at three 
distinct time-points; i) Day 0 - baseline; ii) Day 20 – HFD-induced insulin resistance; and iii) Day 35 – following 
STZ or vehicle delivery.
All glucose tolerance tests were performed on overnight fasted rats. Briefly, animals received an intraperito-
neal injection of glucose (1 g/kg). Blood was accessed from the tip of the tail and glucose concentrations were 
measured at 0, 10, 20, 30, 45, 60, 75, 90, 105 and 120 min following glucose injection. During the day 35 glucose 
tolerance test, larger volumes of blood (2–3 drops) were collected at 0, 10, 20 and 60 min following glucose injec-
tion in pre-heparinised tubes, centrifuged and plasma stored at −20 °C. Plasma insulin (Mercodia Rat Insulin 
ELISA, Uppsala, Sweden) and non-esterified fatty acid concentrations (NEFA-C; Wako Pure Chemical Industries, 
Osaka, Japan) were determined according to the manufacturer’s instructions.
Data and statistics. All data generated or analysed during this study are included in this published article 
(and its Supplementary Information files). Statistics and graphical presentation of data was carried out using 
Sigma Plot 11 (Systat Software, San Jose, CAL, USA). In instances where data was not normally distributed, 
Kruskal-Wallis one way ANOVA on Ranks was utilised with Student-Newman-Keul’s post-hoc. Where data was 
normally distributed, one-way ANOVA with Student-Newman-Keul’s post-hoc was group differences at a single 
time-point and two-way repeated measures ANOVA with Student-Newman-Keul’s post-hoc was utilised for all 
time-course comparisons. A value of p < 0.05 was considered statistically significant.
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